• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.23% Nasdaq Up1.74%

    Catalyst Pharmaceuticals, Inc. (CPRX)

    3.03 Up 0.19(6.69%) Oct 2, 3:59PM EDT
    ProfileGet Profile for:
    Catalyst Pharmaceuticals, Inc.
    355 Alhambra Circle
    Suite 1500
    Coral Gables, FL 33134
    United States - Map
    Phone: 305-529-2522
    Website: http://www.catalystpharma.com

    Index Membership:N/A
    Industry:Drugs - Generic
    Full Time Employees:12

    Business Summary 

    Catalyst Pharmaceuticals, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders. The company offers Firdapse, a proprietary form of amifampridine phosphate, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It is also involved in the development of CPP-115, a GABA aminotransferase inhibitor, which is in Phase Ib clinical trial for the treatment of epilepsy and other selected neurological indications, such as complex partial seizures and Tourette Syndrome; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceuticals, Inc. has a strategic collaboration agreement with BioMarin Pharmaceutical, Inc. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Catalyst Pharmaceuticals, Inc.

    Corporate Governance 
    Catalyst Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Oct 1, 2015 is 8. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 10; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Patrick J. McEnany , 68
    Co-Founder, Chairman, Chief Exec. Officer and Pres
    Ms. Alicia Grande CPA, CMA, 44
    Chief Financial Officer, Chief Accounting Officer, VP and Treasurer
    Dr. Steven R. Miller Ph.D., 53
    Chief Operating Officer and Chief Scientific Officer
    Dr. Gary Ingenito M.D., Ph.D., 59
    Chief Medical Officer
    Mr. Paul J. Merrigan MBA,
    Chief Commercial Officer
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders